Company intelligence / Profile preview

Pionyr Immunotherapeutics

South San Francisco, California, United Statespionyrtx.com ↗

Ownership: Private
Development stage: Other

Overview

Pionyr’s lead assets PY314 and PY159 are monoclonal antibodies targeting myeloid checkpoints TREM2 and TREM1 respectively. Both completed Phase Ia dose-escalation studies showing safety and tolerability as monotherapy or combined with pembrolizumab. Phase Ib expansion studies were underway for both agents in a range of solid tumor types at the time of acquisition. Early data indicated favorable safety profiles and evidence of immune modulation within the tumor microenvironment.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies (mAbs)Biologics
Industry: Biotech

Partnerships

Gilead Sciences held a minority interest with an exclusive option to acquire Pionyr upon completion of certain milestones; strategic collaboration announced July 2020

Beyond the preview

Go deeper on Pionyr Immunotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pionyr Immunotherapeutics.